Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients
Open-label, single-group study (n=9) assessing low-dose IV ketamine (0.5 mg/kg over 40 minutes) on cortical neurophysiological function in treatment-resistant depression.
Details
This open-label treatment study administers a single low-dose intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) to patients with treatment-resistant depression to assess rapid neurophysiological and symptomatic effects.
Outcomes focus on cortical excitability and oscillatory activity measured with TMS–EEG and the auditory steady state response (ASSR) at 40 Hz, alongside clinical depression measures to investigate ketamine-induced changes in glutamate neurotransmission and synaptic plasticity.
Safety monitoring includes vital signs and standard adverse event recording; eligibility excludes major medical, neurological or psychotic disorders, current substance dependence, and pregnancy.